{"id":8889,"date":"2026-10-13T15:00:26","date_gmt":"2026-10-13T09:30:26","guid":{"rendered":"https:\/\/lakshmishree.com\/news\/?p=8889"},"modified":"2026-10-13T15:00:26","modified_gmt":"2026-10-13T09:30:26","slug":"details-of-sahajanand-medical-technologies-limited","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/news\/details-of-sahajanand-medical-technologies-limited\/","title":{"rendered":"Details of Sahajanand Medical Technologies Limited IPO : Lot Size, Check Issue Date, Price"},"content":{"rendered":"\n

Sahajanand Medical Technologies IPO Price:<\/strong> \u20b9327 to \u20b9344 per share<\/p>\n\n\n\n

IPO Dates:<\/strong> 15 to 19 Oct, 2026<\/p>\n\n\n\n

\n
\n
\n
\n
\"\"<\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Company Overview<\/strong><\/h2>\n\n\n\n

Incorporated in October 2001, Sahajanand Medical Technologies Limited is a medical technology company engaged in the development, manufacturing and marketing of technologically advanced medical devices, primarily focused on vascular intervention and structural heart intervention.<\/p>\n<\/div>\n<\/div>\n\n\n\n

Product Portfolio<\/h2>\n\n\n\n

The Company’s product portfolio includes coronary stents, coronary balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs). Its flagship brands include Supraflex Cruz, Cocoon and Hydra, serving different areas of interventional cardiology.<\/p>\n\n\n\n

Research and Development<\/h2>\n\n\n\n

The Company focuses on research and development, precision manufacturing and clinically supported product innovation. As of June 30, 2026, it had 119 patents granted globally, 78 patent applications in the pipeline and five design registrations in India.<\/p>\n\n\n\n

Manufacturing Facilities<\/h2>\n\n\n\n

The Company operates three manufacturing facilities, two in India and one in Thailand, supported by two R&D centres in India and Thailand.<\/p>\n\n\n\n

Global Presence<\/h2>\n\n\n\n

The Company’s products were marketed in 77 countries in Fiscal 2026 through direct, hybrid and distributor-led models, with an established market presence in India, Europe and other international markets.<\/p>\n\n\n\n

Financial Performance<\/h2>\n\n\n\n

The Company reported revenue from operations of \u20b912,105.04 million in Fiscal 2026, compared with \u20b910,248.79 million in Fiscal 2025 and \u20b99,016.04 million in Fiscal 2024.<\/p>\n\n\n\n

Workforce<\/h2>\n\n\n\n

As of June 30, 2026, the Company had 1,605 full-time employees, 31 consultants and 707 contract-based employees.<\/p>\n\n\n\n

Competitive Strengths<\/h2>\n\n\n\n